5AM Venture Management, LLC
CIK: 0001799883Latest portfolio: $318.1M · Q4 2025
Holdings
21
Total Value
$318.1M
New Positions
1
Closed Positions
5
Top Holdings
| # | Stock | Shares | Value | % Portfolio | Change | Type |
|---|---|---|---|---|---|---|
| 1 | TRDAENTRADA THERAPEUTICS INC | 4,056,379 | $41.7M | 13.11% | -200,000 | |
| 2 | CAMPCAMP4 THERAPEUTICS CORP | 5,869,091 | $36.0M | 11.31% | — | |
| 3 | TYRATYRA BIOSCIENCES INC | 1,029,298 | $27.1M | 8.51% | +90K | |
| 4 | VRDNVIRIDIAN THERAPEUTICS INC | 736,595 | $22.9M | 7.21% | — | |
| 5 | PHVSPHARVARIS N V | 797,600 | $22.1M | 6.96% | — | |
| 6 | ERASERASCA INC | 5,405,404 | $20.1M | 6.32% | — | |
| 7 | EYPTEYEPOINT INC | 1,050,000 | $19.2M | 6.03% | — | |
| 8 | MPLTMAPLIGHT THERAPEUTICS INC | 950,011 | $16.7M | 5.25% | NEW | |
| 9 | CNTACENTESSA PHARMACEUTICALS PLC | 580,945 | $14.5M | 4.57% | -100,000 | |
| 10 | TCE2CELLDEX THERAPEUTICS INC NEW | 497,270 | $13.5M | 4.25% | — | |
| 11 | TECXTECTONIC THERAPEUTIC INC | 606,660 | $12.7M | 3.98% | +95K | |
| 12 | ELVNENLIVEN THERAPEUTICS INC | 772,477 | $11.9M | 3.74% | — | |
| 13 | ARTVARTIVA BIOTHERAPEUTICS INC | 2,353,304 | $10.1M | 3.17% | — | |
| 14 | SRZNSURROZEN INC | 387,500 | $8.8M | 2.75% | +78K | |
| 15 | BHVNBIOHAVEN LTD | 738,972 | $8.3M | 2.62% | +260K | |
| 16 | TARAPROTARA THERAPEUTICS INC | 1,369,782 | $7.3M | 2.29% | +570K | |
| 17 | GHRSGH RESEARCH PLC | 572,665 | $7.3M | 2.29% | — | |
| 18 | SKYESKYE BIOSCIENCE INC | 9,681,763 | $7.3M | 2.28% | — | |
| 19 | ZNTLZENTALIS PHARMACEUTICALS INC | 3,947,913 | $5.3M | 1.68% | +3.5M | |
| 20 | SLNSILENCE THERAPEUTICS PLC | 476,200 | $2.9M | 0.91% | — | |
| 21 | RLYBRALLYBIO CORP | 3,630,724 | $2.5M | 0.78% | — |
Quarterly Changes
New Positions
- MPLTNEW$16.7M
Sector Breakdown
Healthcare0.0% ($4.1699359772706026e+82T)
Unknown0.0% ($13.5M)
Filing History
Fund Information
5AM Venture Management, LLC is an institutional investment manager that files 13F reports with the SEC. As of the Q4 2025 filing, the fund reported a portfolio valued at $318.1M across 21 holdings. The largest position is ENTRADA THERAPEUTICS INC (TRDA), representing 13.1% of the portfolio. Compared to the previous quarter, the fund opened 1 new positions and closed 5 positions. 13F filings are required quarterly disclosures that provide transparency into the holdings of institutional investment managers with at least $100 million in qualifying assets.